PEAK6 Investments’s CRISPR Therapeutics CRSP Stock Holding History

PEAK6 Investments’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$399K	Buy	8,500 +3,000	+55%	+$152K	﹤0.01%	2439
2024 Q2	$297K	Sell	5,500 -17,600	-76%	-$1.02M	﹤0.01%	2550
2024 Q1	$1.57M	Buy	23,100 +15,100	+189%	+$1.08M	﹤0.01%	1625
2023 Q4	$501K	Sell	8,000 -48,400	-86%	-$2.68M	﹤0.01%	2612
2023 Q3	$2.56M	Hold	56,400	–	–	0.01%	1173
2023 Q2	$3.17M	Sell	56,400 -82,000	-59%	-$4.65M	0.01%	899
2023 Q1	$6.26M	Sell	138,400 -237,100	-63%	-$11.5M	0.03%	595
2022 Q4	$15.3M	Sell	375,500 -7,500	-2%	-$398K	0.09%	229
2022 Q3	$25M	Sell	383,000 -49,000	-11%	-$3.55M	0.1%	168
2022 Q2	$26M	Buy	432,000 +89,900	+26%	+$5.29M	0.05%	374
2022 Q1	$21.5M	Buy	342,100 +97,100	+40%	+$6.1M	0.05%	378
2021 Q4	$18.6M	Buy	245,000 +114,500	+88%	+$10M	0.04%	440
2021 Q3	$14.6M	Buy	130,500 +19,800	+18%	+$2.49M	0.03%	513
2021 Q2	$17.9M	Sell	110,700 -38,900	-26%	-$4.73M	0.04%	415
2021 Q1	$18.2M	Buy	+149,600	New	+$22.6M	0.04%	385

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PEAK6 Investments's CRSP Position: Q3 2024 in Review

PEAK6 Investments opened a new position in CRISPR Therapeutics (CRSP) in Q3 2024: 297 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #3221 among its holdings. This is a return to the name: PEAK6 Investments previously reported a position in CRSP as recently as Q4 2023.

PEAK6 Investments first reported a position in CRSP in Q1 2021 and has held it in 11 quarters since. The position peaked at $11.1M in Q4 2022. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

PEAK6 Investments held 297 shares of CRISPR Therapeutics worth $14K as of Q3 2024.
CRISPR Therapeutics was a new PEAK6 Investments position in Q3 2024.
CRISPR Therapeutics made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #3221 holding.
PEAK6 Investments first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 11 quarters since.
PEAK6 Investments's CRISPR Therapeutics position peaked at $11.1M in Q4 2022.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.